Skip to main content

Zymergen ditches thin-film program, targets agriculture, vaccines, drugs

Following a $575 million IPO in April, the company's once-lofty prospects blew up after its bio-manufactured thin film for smart phones didn't play nicely with its customers processes.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.